Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

Core Insights - Praxis Precision Medicines, Inc. is set to report topline results from the RADIANT trial of vormatrigine and its financial results for Q2 2025 on August 4, 2025, before market opening [1] - A live webcast will be hosted on the same day at 8:30am ET, accessible via a registration link and available for replay for 90 days [2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, utilizing genetic insights [3] - The company employs proprietary platforms, Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides, to target shared biological mechanisms in the brain [3] - Praxis has a diversified CNS portfolio with multiple programs addressing epilepsy and movement disorders, featuring four clinical-stage product candidates [3]